Revenue: As of FY2025, the actual value is USD 0.EPS: As of FY2025, the actual value is USD -8.93, missing the estimate of USD -6.59.EBIT: As of FY2025, the actual value is USD -5.763 M.<h3>Fourth Quarter 2025 Financial Results</h3><ul><li>Cash Flow from Operations: Cash used in operations increased to $1.6 million in the fourth quarter of 2025, compared with $1.5 million in the fourth quarter of 2024.</li><li>Operating Expenses: Operating expenses decreased to $1.6 million in the fourth quarter of 2025, compared with $4.3 million in the same period last year.</li><li>Net Loss: The net loss for the fourth quarter of 2025 was - $3.2 million, compared with a net loss of - $4.2 million in the fourth quarter of 2024.</li></ul><h3>Full Year 2025 Financial Results</h3><ul><li>Operating Expenses: Operating expenses in 2025 decreased to $5.8 million, compared with $10.8 million in 2024, which included a - $2.3 million non-cash inventory valuation charge.<ul><li>Research and development expenses were $1,849,996 in 2025, down from $3,190,293 in 2024.</li><li>Sales and marketing expenses were $189,470 in 2025, down from $571,040 in 2024.</li><li>General and administrative expenses were $3,723,635 in 2025, down from $7,055,814 in 2024.</li></ul></li><li>Operating Loss: The operating loss was - $5,763,101 in 2025, significantly reduced from - $10,817,147 in 2024.</li><li>Net Loss: The company reported a net loss of - $7.0 million in 2025, an improvement from a net loss of - $11.5 million in 2024, primarily driven by lower operating expenses.</li></ul><h3>Balance Sheet Highlights (as of December 31, 2025)</h3><ul><li>Cash and Cash Equivalents: ENDRA Life Sciences Inc. had approximately $762,000 in cash and cash equivalents.</li><li>Digital Assets: The company held approximately $2.0 million in its Digital Asset Treasury.</li><li>Total Assets: Total assets were $3,853,797 as of December 31, 2025, down from $4,452,362 as of December 31, 2024.</li><li>Total Liabilities: Total liabilities were $1,593,677 as of December 31, 2025, down from $1,891,996 as of December 31, 2024.</li><li>Total Stockholders’ Equity: Total stockholders’ equity was $2,260,120 as of December 31, 2025, down from $2,560,366 as of December 31, 2024.</li><li>Accumulated Deficit: The accumulated deficit was - $110,465,509 as of December 31, 2025, compared to - $103,438,099 as of December 31, 2024.</li></ul><h3>Other Financial Items</h3><ul><li>Change in Fair Value of Digital Assets: The change in fair value of digital assets resulted in a - $995,161 impact in 2025.</li><li>Warrant Expense: Warrant expense was - $665,030 in 2025, a decrease from - $7,323,685 in 2024.</li><li>Changes in Fair Value of Warrant Liability: This resulted in a gain of $319,537 in 2025, compared to a gain of $3,447,737 in 2024.</li></ul><h3>Business Outlook</h3>ENDRA Life Sciences Inc.’s Board of Directors initiated a process on March 25, 2026, to evaluate strategic alternatives aimed at maximizing shareholder value. The company plans to continue executing its strategic and operating initiatives throughout this review process. A timetable for the completion of this evaluation has not been set.

Endra Life Sciences | 8-K: FY2025 Revenue: USD 0